<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27591950</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>42</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria.</ArticleTitle><Pagination><StartPage>5125</StartPage><EndPage>5131</EndPage><MedlinePgn>5125-5131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.08.058</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)30745-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION">In September 2015, Nigeria was removed from the list of polio-endemic countries after more than 12months had passed since the detection of last wild poliovirus case in the country on 24 July 2014. We are presenting here a report of two polio seroprevalence surveys conducted in September 2013 and October 2014, respectively, in the Kano state of northern Nigeria.</AbstractText><AbstractText Label="METHODS">Health facility based seroprevalence surveys were undertaken at Murtala Mohammad Specialist Hospital, Kano. Parents or guardians of children aged 6-9months, 36-47months, 5-9years and 10-14years in 2013 and 6-9months and 19-22months (corresponding to 6-9months range at the time of 2013 survey) in 2014 presenting to the outpatient department, were approached for participation, screened for eligibility and asked to provide informed consent. A questionnaire was administered and a blood sample collected for polio neutralization assay.</AbstractText><AbstractText Label="RESULTS">Among subjects aged 6-9months in the 2013 survey, seroprevalence was 58% (95% confidence interval [CI] 51-66%) to poliovirus type 1, 42% (95% CI 34-50%) to poliovirus type 2, and 52% (95% CI 44-60%) to poliovirus type 3. Among children 36-47months and older, seroprevalence was 85% or higher for all three serotypes. In 2014, seroprevalence in 6-9month infants was 72% (95% CI 65-79%) for type 1, 59% (95% CI 52-66%) for type 2, and 65% (95% CI 57-72%) for type 3 and in 19-22months, 80% (95% CI 74-85%), 57% (49-63%) and 78% (71-83%) respectively. Seroprevalence was positively associated with history of increasing oral poliovirus vaccine doses.</AbstractText><AbstractText Label="CONCLUSIONS">There was significant improvement in seroprevalence in 2014 over the 2013 levels indicating a positive impact of recent programmatic interventions. However the continued low seroprevalence in 6-9month age is a concern and calls for improved immunization efforts to sustain the polio-free Nigeria.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iliyasu</LastName><ForeName>Zubairu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Aminu Kano Teaching Hospital &amp; Bayero University Kano, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Harish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland. Electronic address: vermah@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Kehinde T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nwaze</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad-Shehu</LastName><ForeName>Amina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jibir</LastName><ForeName>Binta Wudil</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Murtala Mohammed Specialist Hospital, Kano, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwarzo</LastName><ForeName>Garba Dayyabu</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Aminu Kano Teaching Hospital &amp; Bayero University, Kano, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gajida</LastName><ForeName>Auwalu U</ForeName><Initials>AU</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Aminu Kano Teaching Hospital &amp; Bayero University Kano, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steven Oberste</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takane</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mkanda</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Ado J G</ForeName><Initials>AJG</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kano</Keyword><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Poliomyelitis</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27591950</ArticleId><ArticleId IdType="pmc">PMC5036508</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.058</ArticleId><ArticleId IdType="pii">S0264-410X(16)30745-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Assembly. Global eradication of poliomyelitis by the year 2000. WHA41.28. [14 September 2015]. Available from: http://www.who.int/ihr/polioresolution4128en.pdf.</Citation></Reference><Reference><Citation>Morales M., Tangermann R.H., Wassilak S.G. Progress toward polio eradication &#x2014; worldwide, 2015&#x2013;2016. MMWR Morb Mortal Wkly Rep. 2016;65:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">27171208</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. Global eradication of wild poliovirus type 2 declared; 2015. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx.</Citation></Reference><Reference><Citation>Kew O.M., Cochi S.L., Jafari H.S., Wassilak S.G., Mast E.E., Diop O.M. Possible eradication of wild poliovirus type 3 &#x2013; worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(45):1031&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779498</ArticleId><ArticleId IdType="pubmed">25393222</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. World Health Organization removes Nigeria from polio endemic list. [15 September 2015]. Available from: http://www.who.int/mediacentre/news/releases/2015/nigeria-polio/en/.</Citation></Reference><Reference><Citation>Noha H.Farag, Zubair Wadood Mufti, Rana Muhammad Safdar, Nabil Ahmed, Sabrine Hamdi, Rudolph H. Tangermann. Progress toward poliomyelitis eradication &#x2014; Pakistan, January 2014&#x2013;September 2015. MMWR Morb Mortal Wkly Rep. 2015;64(45):1271&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">26584026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbaeyi Chukwuma, Saatcioglu Akif, Tangermann Rudolf H., Hadler Stephen, Ehrhardt Derek. Progress toward poliomyelitis eradication &#x2014; Afghanistan, January 2014&#x2013;August 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1166&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">26492280</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. Data and monitoring. Wild poliovirus. [10 August 2016]. Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.</Citation></Reference><Reference><Citation>GPEI. Key countries. Nigeria. [10 August 2016]. Available from: http://www.polioeradication.org/Keycountries/Nigeria(cVDPV).aspx.</Citation></Reference><Reference><Citation>Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203(7):898&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Shaw J., Jorba J., Bukbuk D., Adu F., Gumede N. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol. 2013;87(9):4907&#x2013;4922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliyasu Z., Nwaze E., Verma H., Mustapha A.O., Weldegebriel G., Gasasira A. Survey of poliovirus antibodies in Kano, Northern Nigeria. Vaccine. 2014;32(12):1414&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">24041545</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig K.T., Verma H., Iliyasu Z., Mkanda P., Touray K., Johnson T. Role of serial polio seroprevalence studies in guiding implementation of the polio eradication initiative in Kano, Nigeria: 2011&#x2013;2014. J Infect Dis. 2016;213(Suppl. 3):S124&#x2013;S130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818560</ArticleId><ArticleId IdType="pubmed">26908720</ArticleId></ArticleIdList></Reference><Reference><Citation>Arie S. Murder of nine polio workers in Nigeria threatens eradication efforts. BMJ. 2013;346:f954.</Citation><ArticleIdList><ArticleId IdType="pubmed">23404166</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Report of a WHO informal consultation on polio neutralizing antibody assays. WHO/EPI/RD/91.3 Rev 1; 1991.</Citation></Reference><Reference><Citation>Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia World Health Organization collaborative study group on oral poliovirus vaccine. J Infect Dis. 1995;171(5):1097&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">7751683</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Anthro version 3.2.2; 2011. [14 September 2015]. Available from: http://www.who.int/childgrowth/software/en/.</Citation></Reference><Reference><Citation>WHO. The WHO child growth standards. [08 June 2016]. Available from: http://www.who.int/childgrowth/standards/en/.</Citation></Reference><Reference><Citation>US Census Bureau. Census and survey processing system (CSPro). [14 September 2014]. Available from: http://www.census.gov/population/international/software/cspro/.</Citation></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. Available from: https://www.r-project.org/.</Citation></Reference><Reference><Citation>El-Sayed N., Al-Jorf S., Hennessey K.A., Salama M., Watkins M.A., Abdelwahab J.A. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. Vaccine. 2007;25(27):5062&#x2013;5070.</Citation><ArticleIdList><ArticleId IdType="pubmed">17543428</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz C.F., Jafari H., Sutter R.W., John T.J., Jain V., Agarwal A. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6&#x2013;9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012;12(2):128&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22071249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>